Rating Change
Canaccord Genuity reiterated its Buy rating on TransMedics Group, Inc. (NASDAQ:TMDX) on October 13, 2026.
reiterateNASDAQ:TMDX
Canaccord Genuity Reiterates Buy Rating on TransMedics Group, Inc. (TMDX)
Canaccord Genuity reiterated its Buy rating on TransMedics Group, Inc. (NASDAQ:TMDX) on October 13, 2026.
At publication ·
What changed
TransMedics Group, Inc. (NASDAQ:TMDX) · reiterate
- Firm
- Canaccord Genuity
- Rating
- Buy to Buy
- Price at event
- $79.14
- Market capitalization
- $4.4B
At a glance
Key takeaways
- Canaccord Genuity reiterated a Buy rating on TransMedics Group (TMDX) on October 13, 2026, with the stock trading at $79.14 and a market capitalization of $4.4 billion.
Market Context
TransMedics Group, Inc. operates in the Healthcare sector. The stock currently trades at $79.14 with a market capitalization of $4.4B.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for TransMedics Group, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for TransMedics Group, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | Canaccord Genuity | Buy | N/A |
| Oct 07, 2026 | Barclays | Overweight | N/A |
| Sep 08, 2026 | TD Cowen | Buy | N/A |
| Aug 05, 2026 | Piper Sandler | Overweight | N/A |
| Aug 05, 2026 | UBS | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View TMDX Stock Page
Frequently Asked Questions
What does the Buy rating mean for TMDX?
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on TransMedics Group, Inc. (NASDAQ:TMDX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TMDX forecast page.